前頭側頭型認知症市場- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年薬剤クラス別、疾患適応症別、流通チャネル別、地域別、競合

前頭側頭型認知症（FTD）の世界市場は、2022年に2億4,136万米ドルの評価額に達し、予測期間には堅調な成長が見込まれ、年間平均成長率（CAGR）は6.39%、2028年には3億4,660万米ドルに達すると予測されます。

前頭側頭型疾患は、脳の前頭葉または側頭葉の神経細胞の変性を特徴とする神経疾患です。認知症、進行性核上性麻痺、原発性進行性失語症など様々な疾患を含むこの疾患は、行動、言語、運動、人格に大きな影響を及ぼし、個人の日常生活能力を損なう。前頭側頭葉変性症としても知られる前頭側頭障害は、主に前頭葉と側頭葉に影響を及ぼす脳障害のカテゴリーです。これらの疾患は、神経細胞の進行性喪失と認知症の発症を伴う。通常、前頭側頭葉変性症は40～60歳で発症するが、60歳以降に発症することもあります。診断後の平均余命は約8～10年です。ヘルスケア分野に大きな影響を与えることから、前頭側頭型障害は予測期間中に大幅な成長が見込まれます。

主な市場促進要因

• 1.FTD治療薬の開発と資金提供の増加：非営利団体、疾患擁護団体、民間団体は、患者人口の拡大を受けて、前頭側頭型変性症（FTD）治療薬の開発を積極的に支援しています。前頭側頭変性症協会（AFTD）、ブルーフィールドプロジェクト機構、タウ・コンソーシアム機構、アルツハイマー病発見財団（ADDF）、CurePSP, Inc.などの著名な非営利団体による研究資金提供のイニシアチブは、前頭側頭疾患の治療に焦点を当てた研究活動を刺激する上で極めて重要な役割を果たしています。これらの組織は、FTDやその他の希少神経疾患の進行を遅らせたり止めたりする新規治療薬の試験を目的とした臨床試験と前臨床試験の両方に支援を提供しており、市場の成長に貢献しています。

• 2.助成金および政府からの資金援助助成金および政府からの資金提供は、FTDに焦点を当てた研究イニシアチブを支援するための資源となり、これには疾患の根本的なメカニズムの調査、潜在的な創薬標的の同定、新規治療アプローチの開発などが含まれます。十分な資金援助は、科学者や研究者にとってのFTD研究の魅力を高め、共同研究を促進し、革新的な治療戦略の探求を促進します。助成金と資金援助は、FTDの有望な創薬標的の同定と検証にも役立ち、これは疾患の根本原因に対処する治療法の開発にとって極めて重要です。
• 3.認知症の有病率の増加前頭側頭型障害治療市場は、認知症の有病率の上昇により成長を遂げています。認知症は、脳の異常を含む様々な基礎疾患を示す認知機能障害やコミュニケーション機能障害を包含します。対象疾患の有病率の上昇と、これらの疾患に罹患する老年人口の増加により、市場は拡大すると予測されます。世界保健機関（WHO）によると、世界中で約5,000万人が認知症に罹患しており、毎年約1,000万人が新たに認知症と診断されています。このことは、この分野の継続的な発展を強調しています。記憶喪失、混乱、行動変化、計画困難などの認知障害は、認知症患者が直面する課題のひとつであり、市場の成長に寄与しています。
• 4.政府による研究開発投資の増加：認知症に対する一般的な認識が高まるにつれ、ヘルスケア専門家や一般市民は、FTDを含む様々なタイプの認知症に関する知識を深めています。その結果、FTD症例の認識、診断、管理が向上しています。FTDの有病率の増加により、その根本的な原因やメカニズムの解明に対する関心が高まっています。そのため、より多くの研究資金が集められ、FTDに特化した研究や研究開発の進展が促進されています。FTDの有病率の増加に伴い、FTDを他の認知症と区別するための正確で早期の診断ツールが必要とされています。診断技術の改善に対する需要がFTD市場の技術革新を促進しています。
• 5.正確な診断のための技術の進歩：技術の進歩は、前頭側頭型認知症（FTD）市場の活性化に重要な役割を果たしています。これらの進歩により、より正確な診断、患者管理の改善、革新的な治療、FTD患者とその介護者に対するサポート体制の強化が可能になります。陽電子放射断層撮影法（PET）や機能的磁気共鳴画像法（fMRI）などの最先端の画像技術は、FTD患者の脳の構造と機能に関する深い洞察を提供し、FTDのサブタイプに関連する脳の萎縮と機能障害の特定のパターンを特定することで、早期かつ正確な診断に役立ちます。また、技術の進歩により、FTDに関連するバイオマーカーの同定と検証も容易になり、早期発見、疾患進行の追跡、治療効果の評価が可能になります。遺伝子解析技術の進歩は、FTDに関連する遺伝子変異の同定を可能にし、疾患の根底にある遺伝的基盤の理解を深めることに貢献します。技術的ツールにより、個人の遺伝的・分子的プロファイルに基づいた個別化治療法の開発が可能になり、特定のFTDサブタイプや患者の特性に合わせた治療法の開発が期待されています。遠隔医療および遠隔モニタリング技術により、ヘルスケア専門家は、患者が医療施設に出向くことなくFTD患者の認知および機能状態を評価することができ、特に移動や移動に制限のある患者にとって有益です。

主な市場課題

• 1.神経疾患の誤診：前頭側頭型障害は、うつ病、パーキンソン病、アルツハイマー病、その他の精神疾患など、他の神経疾患や精神疾患と誤診されることが多いです。このような誤診は、前頭側頭型障害に対する適切な治療の開始を遅らせたり、効果のない、あるいは有害な治療を行うことにつながります。正確な診断は、適切な管理と時宜を得た介入のために極めて重要です。誤診は、不必要な医療費、時間と資源の浪費、効果的な治療の機会を逃すことにつながります。また、患者が前頭側頭型障害の臨床試験に参加できなくなり、標的治療法の開発の妨げになることもあります。
• 2.治験の失敗：臨床試験の高い失敗率

前頭側頭障害を含む神経疾患領域における臨床試験の失敗率の高さは、これらの疾患に対する治療法の成長見通しに影響を与える重大な課題となっています。臨床試験の失敗は、時間、資源、資金の多大な投資を意味し、革新的な治療法の利用を遅らせる。臨床試験の失敗は、製薬会社、研究機関、投資家の経済的損失につながり、将来の研究開発イニシアチブに影響を与えます。試験に失敗すると、研究の方向性が特定のターゲットやアプローチからずれ、全体的な進歩が遅れ、研究者が神経疾患に対する革新的な治療アプローチを追求する意欲を失う可能性があります。臨床試験の失敗に起因する治療法の成功の欠如は、患者やヘルスケアプロバイダーに治療の選択肢を少なくすることで、市場の成長を制限する可能性があります。

主な市場動向：

• 1.新薬承認の増加と先進治療：前頭側頭型障害に対する新薬の承認は、疾患の進行を遅らせ、症状を管理し、生活の質を改善する可能性のある治療へのアクセスを患者に提供します。そのため、FTD患者やヘルスケアプロバイダーの間で、治療に対する需要が高まっています。効果的な治療法には、診断法、バイオマーカー、スクリーニングツールの改善が伴うことが多く、早期診断や患者の特定が容易になります。薬剤の承認はメディアの注目を集め、患者、介護者、一般市民の認識を高め、FTDの診断と治療の選択肢を求める人々の増加につながります。
• 2.FDAによる希少疾病用医薬品開発奨励金：米国食品医薬品局（FDA）による希少疾病用医薬品の開発奨励措置は、前頭側頭型認知症（FTD）市場における治療需要を大幅に押し上げる可能性があります。希少疾病用医薬品は、FTDのような神経変性疾患の多くを含む、希少疾病や疾患の治療を目的としています。FDAは、希少疾病用医薬品の開発に携わる医薬品開発企業に対し、薬事申請や販売申請の手数料を減額するなど、一定の経済的インセンティブを提供しています。FDAの承認を得た希少疾病用医薬品には、市場独占権の延長が認められ、FTD治療にとってより有利な商業環境が構築されます。

セグメント別の洞察

薬剤クラス別の洞察前頭側頭型障害治療の世界市場は、抗精神病薬、認知機能改善薬、中枢神経刺激薬、抗うつ薬など、さまざまな薬剤クラス別に区分されます。中でも抗うつ薬は、予測期間中に有利な機会をもたらすと期待されています。抗うつ薬は主に、抑うつ障害や、ジスティミア、強迫性障害（OCD）、不安障害、神経障害性疼痛、摂食障害、慢性疼痛などを含むその他の疾患の疼痛管理に使用されます。選択的セロトニン再取り込み阻害薬（SSRI）は前頭側頭型障害の治療に有益であることが証明されています。

疾患適応の洞察前頭側頭型認知症は、2022年に前頭側頭型認知症市場で最大の市場シェアを占め、予測期間中も成長が予測されます。原発性進行性失語症は予測期間中に最も高い複合年間成長率を示すと予測されます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 前頭側頭型認知症の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別（認知機能改善薬、抗精神病薬、抗うつ薬、中枢神経刺激薬、その他の薬剤クラス）
  • 適応疾患別（前頭側頭型認知症、原発性進行性失語症、運動障害）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第7章 北米の前頭側頭型認知症市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州前頭側頭型認知症市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第9章 アジア太平洋前頭側頭型認知症市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米前頭側頭型認知症市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカ前頭側頭型認知症市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • 適応疾患別
  • 流通チャネル別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品上市

第14章 前頭側頭型認知症の世界市場SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Business Overview
• Service Offerings
• Recent Developments
• Key Personnel
• SWOT Analysis
  • Transposon Therapeutics
  • Alector Inc.
  • Denali Therapeutics Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Frontotemporal Dementia (FTD) Market reached a valuation of USD 241.36 Million in 2022 and is poised for robust growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.39% and expected to reach USD 346.60 Million through 2028. Frontotemporal diseases represent a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which encompasses various disorders such as dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly affects behavior, language, movement, and personality, impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a category of brain disorders primarily impacting the frontal and temporal lobes. These conditions involve the progressive loss of nerve cells and the development of dementia. Typically, frontotemporal disorders manifest between the ages of 40 and 60, although onset can occur after the age of 60. Following diagnosis, individuals with frontotemporal disorders have an average life expectancy of approximately 8-10 years. Given its substantial impact on the healthcare sector, frontotemporal disorders are expected to experience significant growth in the forecast period.

Key Market Drivers:

• 1. Increasing FTD Drug Development and Funding: Non-profit organizations, disease advocacy groups, and private entities are actively supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from prominent non-profit organizations like the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a pivotal role in stimulating research efforts focused on treating frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can slow down or halt the progression of FTD and other rare neurological diseases, contributing to market growth.

• 2. Grants and Government Funding: Grants and funding provide resources to support FTD-focused research initiatives, including investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Adequate funding enhances the attractiveness of FTD research for scientists and researchers, fosters collaboration, and facilitates the exploration of innovative therapeutic strategies. Grants and funding also assist in the identification and validation of promising drug targets for FTD, which is crucial for developing treatments that address the root causes of the disease.

• 3. Increasing Prevalence of Dementia: The Frontotemporal Disorders Treatment Market is witnessing growth due to the rising prevalence of dementia. Dementia encompasses cognitive and communicative dysfunction, indicative of various underlying conditions, including brain abnormalities. The market is projected to expand due to the growing prevalence of target diseases and a rising geriatric population affected by these conditions. According to the World Health Organization, approximately 50 million individuals worldwide suffer from dementia, with around 10 million new cases diagnosed annually. This underscores the continued development of this sector. Cognitive deficits such as memory loss, confusion, behavioral changes, and planning difficulties are among the challenges faced by individuals with dementia, contributing to market growth.

• 4. The Rising Investment in Research and Development by Governments: As general awareness about dementia increases, healthcare professionals, and the public are becoming more knowledgeable about different types of dementia, including FTD. This results in better recognition, diagnosis, and management of FTD cases. The growing prevalence of FTD has led to increased interest in understanding its underlying causes and mechanisms. This has attracted more research funding, driving advancements in FTD-specific research and drug development. With a higher prevalence of FTD, there is a need for accurate and early diagnostic tools to distinguish FTD from other forms of dementia. The demand for improved diagnostic technologies is driving innovation in the FTD market.

• 5. Technological Advancements for Accurate Diagnosis: Technological advancements are playing a crucial role in boosting the Frontotemporal Dementia (FTD) market. These advancements enable more accurate diagnosis, improved patient management, innovative treatments, and enhanced support systems for individuals with FTD and their caregivers. Cutting-edge imaging technologies such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) provide deeper insights into the brain structure and function of individuals with FTD, aiding in early and accurate diagnosis by identifying specific patterns of brain atrophy and dysfunction associated with FTD subtypes. Technological advancements also facilitate the identification and validation of biomarkers associated with FTD, enabling earlier detection, tracking of disease progression, and assessment of treatment efficacy. Advances in genetic analysis techniques allow for the identification of genetic mutations associated with FTD, contributing to a better understanding of the disease's underlying genetic basis. Technological tools enable the development of personalized treatment approaches based on an individual's genetic and molecular profile, holding promise for tailoring therapies to specific FTD subtypes and patient characteristics. Telemedicine and remote monitoring technologies allow healthcare professionals to assess FTD patients' cognitive and functional status without requiring them to visit healthcare facilities, particularly beneficial for patients with mobility or transportation limitations.

Key Market Challenges:

• 1. Misdiagnosis of Neurological Disorders: Frontotemporal disorders are often misdiagnosed as other neurological or psychiatric conditions such as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric disorders. This misdiagnosis can lead to delayed initiation of appropriate treatment for frontotemporal disorders and ineffective or even harmful treatments. Accurate diagnosis is crucial for proper management and timely intervention. Misdiagnosis can result in unnecessary medical expenses, wasted time and resources, and missed opportunities for effective treatments. It can also exclude patients from participating in clinical trials for frontotemporal disorders, hindering the development of targeted therapies.

• 2. Drug Trial Failures: The high rate

of clinical trial failures in the field of neurological conditions, including frontotemporal disorders, poses a significant challenge that impacts the growth prospects of treatments for these conditions. Clinical trial failures represent a substantial investment of time, resources, and funding, delaying the availability of innovative treatments. Failed trials can lead to financial losses for pharmaceutical companies, research institutions, and investors, impacting future research and development initiatives. Failed trials can result in a shift in research direction, away from certain targets or approaches, slowing overall progress, and discouraging researchers from pursuing innovative treatment approaches for neurological conditions. The lack of successful treatments resulting from clinical trial failures can limit market growth by offering fewer treatment options for patients and healthcare providers.

Key Market Trends:

• 1. Higher Drug Approvals and Advanced Treatment: The approval of new drugs for frontotemporal disorders provides patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools, facilitating early diagnosis and patient identification. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public, leading to more individuals seeking diagnosis and treatment options for FTD.

• 2. Orphan Drug Development Incentives by FDA: The orphan drug development incentives provided by the U.S. Food and Drug Administration (FDA) have the potential to significantly boost the demand for treatments in the Frontotemporal Dementia (FTD) market. Orphan drugs are intended to treat rare diseases and conditions, including many neurodegenerative disorders like FTD. The FDA provides certain financial incentives to drug developers working on orphan drugs, including reduced fees for regulatory submissions and marketing applications. Orphan drugs that receive FDA approval are granted extended market exclusivity, creating a more favorable commercial environment for FTD treatments.

Segmental Insights:

Drug Class Insights: The global market for the treatment of frontotemporal disorders is segmented into various drug classes, including antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to present lucrative opportunities during the forecast period. Antidepressant drugs are primarily used for the management of depressive disorders and other conditions, including dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

Disease Indication Insights: Frontotemporal Dementia accounted for the largest market share in the Frontotemporal Dementia Market in 2022 and is projected to grow during the forecast period. Primary Progressive Aphasia is expected to exhibit the highest compound annual growth rate during the forecast period.

Regional Insights: North America emerged as the dominant player in the Frontotemporal Disorders Treatment Market in 2022, driven by growing awareness, advanced healthcare facilities, and rising income levels. The Asia Pacific region is projected to witness a higher compound annual growth rate (CAGR) during the forecast period, fueled by increasing prevalence of frontotemporal disorders and favorable reimbursement policies.

Key Market Players

• Transposon Therapeutics
• Alector Inc.
• Denali Therapeutics Inc.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Prevail Therapeutics
• Wave Life Sciences
• AstraZeneca plc
• GlaxoSmithKline plc
• TauRx Pharmaceuticals Ltd.

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

• Cognitive Enhancers
• Antipsychotics
• Antidepressants
• CNS Stimulants
• Other Drug Classes

Frontotemporal Dementia Market, By Disease Indication:

• Frontotemporal Dementia
• Primary Progressive Aphasia
• Movement Disorders

Frontotemporal Dementia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Frontotemporal Dementia Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

• Global Frontotemporal Dementia market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Application
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Frontotemporal Dementia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
  • 6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Region
  • 6.2.5. By Company (2022)
• 6.3. Market Map

7. North America Frontotemporal Dementia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Frontotemporal Dementia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Canada Frontotemporal Dementia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Mexico Frontotemporal Dementia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel

8. Europe Frontotemporal Dementia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Frontotemporal Dementia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Italy Frontotemporal Dementia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. France Frontotemporal Dementia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Spain Frontotemporal Dementia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Frontotemporal Dementia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Frontotemporal Dementia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. India Frontotemporal Dementia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Japan Frontotemporal Dementia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. South Korea Frontotemporal Dementia Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Disease Indication
      • 9.3.4.2.3. By Distribution Channel
  • 9.3.5. Australia Frontotemporal Dementia Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Drug Class
      • 9.3.5.2.2. By Disease Indication
      • 9.3.5.2.3. By Distribution Channel

10. South America Frontotemporal Dementia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Frontotemporal Dementia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Argentina Frontotemporal Dementia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Colombia Frontotemporal Dementia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Frontotemporal Dementia Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Class
  • 11.2.2. By Disease Indication
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Frontotemporal Dementia Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Class
      • 11.3.1.2.2. By Disease Indication
      • 11.3.1.2.3. By Distribution Channel
  • 11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Class
      • 11.3.2.2.2. By Disease Indication
      • 11.3.2.2.3. By Distribution Channel
  • 11.3.3. UAE Frontotemporal Dementia Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Class
      • 11.3.3.2.2. By Disease Indication
      • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. Competitive Landscape

• 16.1. Business Overview
• 16.2. Service Offerings
• 16.3. Recent Developments
• 16.4. Key Personnel
• 16.5. SWOT Analysis
  • 16.5.1. Transposon Therapeutics
  • 16.5.2. Alector Inc.
  • 16.5.3. Denali Therapeutics Inc.
  • 16.5.4. Pfizer Inc.
  • 16.5.5. Johnson & Johnson Services Inc.
  • 16.5.6. Prevail Therapeutics
  • 16.5.7. Wave Life Sciences
  • 16.5.8. AstraZeneca plc
  • 16.5.9. GlaxoSmithKline plc
  • 16.5.10. TauRx Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer